GlassScriptPhysician profile
Joseph D Courage
NPI 1225661135
$1,728.33
in general payments reported to CMS, 2019-2025
18 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $646 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.85 | 2024-2025 | |
| Novo Nordisk INC | $355.30 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $167.15 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $138.46 | 2024-2025 | Korlym |
| Lundbeck LLC | $128.65 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $84.42 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $72.24 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $44.10 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $42.06 | 2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $39.33 | 2024-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $37.09 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $32.22 | 2025 | Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.51 | 2025 | Caplyta |
| Pfizer INC. | $22.77 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.33 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.03 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $16.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.85 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Courage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.